PremiumCompany AnnouncementsAlterity Therapeutics Reports Positive Phase 2 Trial Results for MSA Treatment Alterity Therapeutics reports cash balance of A$17.96M as of March 31 Alterity Therapeutics Announces Director Securities Changes PremiumCompany AnnouncementsAlterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment Alterity Therapeutics Reports Progress and Financial Results Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results PremiumThe FlyAlterity Therapeutics Ltd (ADR) trading halted, news pending Alterity Therapeutics downgraded to Hold from Speculative Buy at Benchmark Alterity Therapeutics price target raised to $12 from $8 at Maxim 
